UM

Browse/Search Results:  1-10 of 12 Help

Selected(0)Clear Items/Page:    Sort:
The development of small-molecule inhibitors targeting hexokinase 2 Journal article
Shen Wenying, Zhou Yan, TAM KIN YIP. The development of small-molecule inhibitors targeting hexokinase 2[J]. Drug Discovery Today, 2022, 27(9), 2574-2585.
Authors:  Shen Wenying;  Zhou Yan;  TAM KIN YIP
Adobe PDF | Favorite | TC[WOS]:22 TC[Scopus]:20  IF:6.5/7.3 | Submit date:2024/08/29
Cancer Metabolism  Hexokinase 2  Drug–target Binding  Selective Inhibition  Structure-based Molecular Design  
Bulleyaconitine A is a sensitive substrate and competitive inhibitor of CYP3A4: One of the possible explanations for clinical adverse reactions Journal article
Li, Xiaocui, Ou, Xiaowen, Ni, Jiadong, Xu, Yihong, Zuo, Huilin, Fu, Yu, Yang, Caihua, Zhao, Zhongxiang, Li, Na, Zhou, Hua, Zhang, Rong, Liu, Zhongqiu, Fu, Ling, Zhu, Lijun. Bulleyaconitine A is a sensitive substrate and competitive inhibitor of CYP3A4: One of the possible explanations for clinical adverse reactions[J]. Toxicology and Applied Pharmacology, 2022, 445.
Authors:  Li, Xiaocui;  Ou, Xiaowen;  Ni, Jiadong;  Xu, Yihong;  Zuo, Huilin; et al.
Favorite | TC[WOS]:2 TC[Scopus]:2  IF:3.3/3.6 | Submit date:2023/01/30
Adverse Reaction  Bulleyaconitine a  Cytochrome P450 Enzymes  Drug-drug Interactions  Human Liver Microsomes  Metabolism  
Host UDP-glucuronosyltransferases (UGTs) – gut microbial β-glucuronidases (GUSs) axis in metabolic homeostasis and drug exposure Presentation
报告日期: 2022-06-01
Authors:  Yan, Ru
Favorite |  | Submit date:2022/08/30
Gut Microbial Metabolism  Host Udp-glucuronosyltransferases  Gut Microbial Β-glucuronidases  Host Ugts – Gut Microbial Guss Axis  Metabolic Homeostasis  Drug Exposure  
The development of small-molecule inhibitors targeting hexokinase 2 Review article
2022
Authors:  Shan, Wenying;  Zhou, Yan;  Tam, Kin Yip
Favorite | TC[WOS]:22 TC[Scopus]:20  IF:6.5/7.3 | Submit date:2022/08/05
Cancer Metabolism  Hexokinase 2  Drug–target Binding  Selective Inhibition  Structure-based Molecular Design  
Human gut bacterial β-glucuronidase inhibition: An emerging approach to manage medication therapy Journal article
Wang, Panpan, Jia, Yifei, Wu, Rongrong, Chen, Zhiqiang, Yan, Ru. Human gut bacterial β-glucuronidase inhibition: An emerging approach to manage medication therapy[J]. Biochemical Pharmacology, 2021, 190, 114566.
Authors:  Wang, Panpan;  Jia, Yifei;  Wu, Rongrong;  Chen, Zhiqiang;  Yan, Ru
Favorite | TC[WOS]:30 TC[Scopus]:41  IF:5.3/5.2 | Submit date:2021/12/08
Β-glucuronidases  Gut Microbial Metabolism  Drug Toxicity  Gus Inhibitor  Gut Microbiota  
Recent developments of human monocarboxylate transporter (hMCT) inhibitors as anticancer agents Journal article
Wu Pahau, Zhou Yan, Guo Yizhen, Shaolin Zhang, TAM KIN YIP. Recent developments of human monocarboxylate transporter (hMCT) inhibitors as anticancer agents[J]. Drug Discovery Today, 2021, 26(3), 836-844.
Authors:  Wu Pahau;  Zhou Yan;  Guo Yizhen;  Shaolin Zhang;  TAM KIN YIP
Adobe PDF | Favorite | TC[WOS]:14 TC[Scopus]:13  IF:6.5/7.3 | Submit date:2024/08/29
Antineoplastic Agents  Drug Design  Drug Development  Glucose/metabolism  Glycolysis  Humans Monocarboxylic Acid Transporters  
Advances in Gut Microbial Drug Metabolism Journal article
Yifei Jia, Panpan Wang, Yijia Chen, Ru Yan. Advances in Gut Microbial Drug Metabolism[J]. 药学进展 Progress in Pharmaceutical Sciences, 2020, 44(2), 83-99.
Authors:  Yifei Jia;  Panpan Wang;  Yijia Chen;  Ru Yan
Adobe PDF | Favorite |  | Submit date:2022/08/12
Gut Microbiota  Drug Metabolism  Host Drug Disposition  Precision Medicine  Β-glucuronidases  
Zebrafish as a new model for drug metabolism and high content screen of natural product Conference paper
Lee, SMY, Hoi, PM, Yan, R, Wang, YQ, Han, YF, Chu, IK. Zebrafish as a new model for drug metabolism and high content screen of natural product[C], 2014.
Authors:  Lee, SMY;  Hoi, PM;  Yan, R;  Wang, YQ;  Han, YF; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0 | Submit date:2020/03/26
Drug Metabolism  Chinese Medicine  Zebrafish  Neurodegeneration  Vascular Disease  
Nanosuspension Development of scutellarein as an active and rapid orally absorbed precursor of its BCS class IV glycoside scutellarin Journal article
XIAO YANG, XIAOQING MIAO, ANGRUI CAO, SHANG LI, NANA AI, QI CHANG, SIMON M. Y. LEE, YING ZHENG. Nanosuspension Development of scutellarein as an active and rapid orally absorbed precursor of its BCS class IV glycoside scutellarin[J]. Journal of Pharmaceutical Sciences, 2014, 103(11), 3576-3584.
Authors:  XIAO YANG;  XIAOQING MIAO;  ANGRUI CAO;  SHANG LI;  NANA AI; et al.
Favorite | TC[WOS]:15 TC[Scopus]:21 | Submit date:2018/11/06
Absorption  Cerebral Hemorrhage  Metabolism  Nanotechnology  Oral Drug Delivery  Precursor  Scutellarin (Sg)  Solubility  Zebrafish  
Zebrafish as a new model for drug metabolism and high content screen of natural product Journal article
Lee, SMY, Hoi, PM, Yan, R, Wang, YQ, Han, YF, Chu, IK. Zebrafish as a new model for drug metabolism and high content screen of natural product[J]. PLANTA MEDICA, 2014, 80(16).
Authors:  Lee, SMY;  Hoi, PM;  Yan, R;  Wang, YQ;  Han, YF; et al.
Favorite | TC[WOS]:0   IF:2.1/2.8 | Submit date:2020/03/26
Neurodegeneration  Chinese Medicine  Zebrafish  Drug Metabolism  Vascular Disease